SciSparc Ltd - Strategic SWOT Analysis Review

November 2021 | 32 pages | ID: SC61D9B63697EN
GlobalData

Abstracts

SciSparc Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

SciSparc Ltd (SciSparc), formerly Therapix Biosciences Ltd, is a clinical-stage biopharmaceutical company that focuses on the development of cannabinoid-based pharmaceuticals for the treatment of central nervous system disorders. SciSparc’s major product candidates include SCI-110, for the treatment of Tourette Syndrome (TS), Obstructive Sleep Apnea (OSA), and Alzheimer’s disease and agitation; SCI-210, for the treatment of Autism Spectrum Disorder (ASD) and epilepsy; and SCI-160, for the treatment of pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. SciSparc is headquartered in Tel Aviv, Israel.

SciSparc Ltd Key Recent Developments

May 12,2021: SciSparc to support 31st annual ICRS Symposium on cannabinoids special event
Feb 11,2021: SciSparc announces rebranding and business updates
Feb 09,2021: SciSparc initiates commercial production of its CannAmide pills
Jan 28,2021: Therapix Biosciences announces name change to SciSparc
Aug 21,2020: Therapix Biosciences announces replacement of its Board of Directors

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

SciSparc Ltd - Key Facts
SciSparc Ltd - Key Employees
SciSparc Ltd - Key Employee Biographies
SciSparc Ltd - Major Products and Services
SciSparc Ltd - History
SciSparc Ltd - Company Statement
SciSparc Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
SciSparc Ltd - Business Description
SciSparc Ltd - SWOT Analysis
SWOT Analysis - Overview
SciSparc Ltd - Strengths
SciSparc Ltd - Weaknesses
SciSparc Ltd - Opportunities
SciSparc Ltd - Threats
SciSparc Ltd - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
SciSparc Ltd, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

May 12, 2021: SciSparc to support 31st annual ICRS Symposium on cannabinoids special event
Feb 11, 2021: SciSparc announces rebranding and business updates
Feb 09, 2021: SciSparc initiates commercial production of its CannAmide pills
Jan 28, 2021: Therapix Biosciences announces name change to SciSparc
Aug 21, 2020: Therapix Biosciences announces replacement of its Board of Directors
Jul 01, 2020: Therapix Biosciences receives Notice of Delisting and Injunction from Israeli Court
May 07, 2020: Therapix Biosciences appoints Prof. Ari Shamiss (M.D., M.P.A.) to the company's board of directors
Apr 22, 2020: Therapix Biosciences announces appointment of new CEO

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

SciSparc Ltd, Key Facts
SciSparc Ltd, Key Employees
SciSparc Ltd, Key Employee Biographies
SciSparc Ltd, Major Products and Services
SciSparc Ltd, History
SciSparc Ltd, Subsidiaries
SciSparc Ltd, Key Competitors
SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
SciSparc Ltd, Recent Deals Summary

List Of Figures

LIST OF FIGURES

SciSparc Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
SciSparc Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021